breast cancer patient.
Conditions
Interventions
Intervention 1: First intervention group: Administration of a single oral dose of 30 mg soft gelatin capsule of vinorelbine (Sana Pharmed Pharmaceutical Co., Iran) in one period of a randomized two-pe
Sponsors
Sana pharmed
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: patients with breast cancer
Exclusion criteria
Exclusion criteria: Smoking Alcohol and drug abuse Abnormal liver or kidney function AIDS, HBV, HCV, syphilis Abnormal WBC, hemoglobin, or platelets History of acute or chronic GI, liver, kidney, or cardiovascular disease Candidates with a neutrophil count less than 500/mm3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug concentration in blood. Timepoint: 0.5? 1.0? 1.5? 2.0? 2.5? 3.0? 3.5? 4.0? 5? 6 ? 8? 10? 12? 24 ? 48, 72 hours after drug administration. Method of measurement: Liquid Chromatography with Mass-Mass Detector. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to reach maximum blood concentration. Timepoint: After intervention. Method of measurement: The time to reach the maximum drug concentration in blood is recorded. This is done after completing the instrumental analysis of the samples using the WinNonLin software developed by Phoenix Company.;Extent of absorption. Timepoint: After intervention. Method of measurement: Calculation of area under curve of concentration -time plots. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJavad Shokri
Tabriz University of Medical Sciences
Outcome results
None listed